Emmett Elledge, MD
Otolaryngology · Birmingham, ALNPI 1437282787
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,450 of the $6,179 with a category attached, or 88.2%. 27 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 42.0% of the total. Reporting peaked in 2021 at $1,662 and has fallen 54.5% since, to $756 in 2025.
Across 177 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- Optinose US, Inc.$739
- Intersect ENT, Inc.$466
- GSK$417
- Aroa Biosurgery Incorporated$402
- Sanofi$313
- plus $1K from 21 others
What the payments were for
- Travel & lodging$72912%
- Food & beverage$5,45088%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 34 | $2,593 |
| Optinose US, Inc. | 50 | $739 |
| Intersect ENT, Inc. | 10 | $466 |
| GSK | 21 | $417 |
| Aroa Biosurgery Incorporated | 6 | $402 |
| Sanofi | 10 | $313 |
| Regeneron Healthcare Solutions, Inc. | 14 | $299 |
| Stryker | 5 | $214 |
| Medtronic | 5 | $203 |
| Neurent Medical Limited | 2 | $145 |
| Integra Lifesciences Corporation | 2 | $55 |
| Smith+Nephew | 2 | $54 |
| Cook Medical LLC | 2 | $33 |
| Aerin Medical Inc. | 1 | $30 |
| Amgen | 1 | $25 |
| Olympus America Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Merck | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Acclarent, Inc | 1 | $18 |
| Davol Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Glenmark Therapeutics Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$1,714
- Inspire$214
- CLARIFIX$126
- PROPEL$119
How this compares
$6,179 in reported general payments places this provider in the 85th percentile of 155 otolaryngology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 757 | $25,202 |
| Fluticasone Propionate | 676 | $9,554 |
| XhanceFluticasone Propionate | 11 | $7,631 |
| Epinephrine | 24 | $6,449 |
| Mometasone Furoate | 164 | $4,149 |
| Clarithromycin | 84 | $2,114 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 150 | $2,049 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 21 | $1,594 |
| Montelukast Sodium | 175 | $1,424 |
| Fluconazole | 34 | $1,234 |
| Methylprednisolone | 130 | $1,232 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 95 | $1,094 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 11 | $574 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $531 |
| Ipratropium Bromide | 21 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $739 | $7,63111 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $6,44924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 155 otolaryngology providers in Alabama.
Other otolaryngology in Birmingham
- Michael SillersBirmingham$53K
- Justin TurnerBirmingham$34K
- Bradford WoodworthBirmingham$27K
- Patrick OwensBirmingham$26K
- Kirk WithrowBirmingham$22K
- Do-Yeon ChoBirmingham$19K
- Andrew FusonBirmingham$18K
- Benjamin GreeneBirmingham$15K
- William BarberBirmingham$13K
- Dennis PappasBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.